Targeting PD-1/PD-L1 interactions for cancer immunotherapy

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1223-1225

  Zitvogel, Laurence ^a,b   Kroemer, Guido ^a,c,d,e,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut Gustave Roussy   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; BMS 936559; CD28 ANTIGEN; CT 110; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC AGENT; INTERLEUKIN 2; INTERLEUKIN 8; MK 3475; MPDL 3280A; NIVOLUMAB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; EDITORIAL; HUMAN; IMMUNOTOXICITY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STOMACH CANCER; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84877896663     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21335     Document Type: Editorial

References (33)

1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
3. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-24; PMID:17606980; http://dx.doi.org/10.1093/intimm/dxm057.
4. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195-201; PMID:16500147; http://dx.doi.org/10.1016/j.it.2006.02.001.
5. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203:883-95; PMID:16606670; http://dx.doi.org/10.1084/jem.20051776.
6. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193:839-46; PMID:11283156; http://dx.doi.org/10.1084/jem.193.7.839.
7. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876.
8. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 2008; 105:9331-6; PMID:18599457; http://dx.doi.org/10.1073/pnas.0710441105.
9. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099.
10. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007; 110:180-5; PMID:17289811; http://dx.doi.org/10.1182/blood-2006-11-060087.
11. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25:9543-53; PMID:16227604; http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005.
12. Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 2000; 191:891-8; PMID:10704469; http://dx.doi.org/10.1084/jem.191.5.891.
13. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005; 6:280-6; PMID:15685176; http://dx.doi.org/10.1038/ni1165.
14. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198:63-9; PMID:12847137; http://dx.doi.org/10.1084/jem.20022125.
15. Titanji K, Velu V, Chennareddi L, Vijay-Kumar M, Gewirtz AT, Freeman GJ, et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest 2010; 120:3878-90; PMID:20972331; http://dx.doi.org/10.1172/JCI43271.
16. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010; 11:535-42; PMID:20453843; http://dx.doi.org/10.1038/ni.1877.
17. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29; PMID:20008522; http://dx.doi.org/10.1084/jem.20090847.
18. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008; 205:565-74; PMID:18283119; http://dx.doi.org/10.1084/jem.20071477.
19. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105:7797-802; PMID:18509048; http://dx.doi.org/10.1073/pnas.0800928105.
20. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517.
21. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1- dependent immunosuppression in cancer. Cancer Res 2011; 71:5393-9; PMID:21724589; http://dx.doi.org/10.1158/0008-5472.CAN-11-0993.
22. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, et al. Cancer-Induced Immunosuppression: IL-18-Elicited Immunoablative NK Cells. Cancer Res 2012; 72:2757-67; PMID:22427351; http://dx.doi.org/10.1158/0008-5472.CAN-11-3379.
23. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8:190-8; PMID:16611412; http://dx.doi.org/10.1593/neo.05733.
24. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:3360-5; PMID:17360651; http://dx.doi.org/10.1073/pnas.0611533104.
25. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID:17404099; http://dx.doi.org/10.1158/1078-0432.CCR-06-2746.
26. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11:2947-53; PMID:15837746; http://dx.doi.org/10.1158/1078-0432.CCR-04-1469.
27. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899.
28. Wilcox RA, Ansell SM, Lim MS, Zou W, Chen L. The B7 homologues and their receptors in hematologic malignancies. Eur J Haematol 2012; 88:465-75; PMID:22372959; http://dx.doi.org/10.1111/j.1600-0609.2012.01766.x.
29. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101:17174-9; PMID:15569934; http://dx.doi.org/10.1073/pnas.0406351101.
30. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303.
31. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:27-37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689.
32. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-22; PMID:17629517; http://dx.doi.org/10.1016/j.immuni.2007.05.016.
33. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009.